|Bid||54.04 x 800|
|Ask||0.00 x 800|
|Day's Range||55.72 - 57.17|
|52 Week Range||29.01 - 58.93|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||27.82|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.75|
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the successful completion of the first human surgical procedure with its injectable HA-based bone repair therapy for the treatment of bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. The case was performed by Dr. John J. Tierney, an orthopedic surgeon at the New England Baptist Hospital and President of the Greater Boston Orthopedic Center. Approximately 900,000 people require treatment for bone voids and other bone defects of the knee, which cause pain and impaired function that can lead to the need for total joint replacement therapy.
Anika Therapeutics received an upgrade to 'Buy' on Monday from TheStreet.com's quantitative service which comes on the heels of its technical breakout last week. In this daily bar chart of ANIK, below, we can see a year-long base pattern with an upside gap/breakout. The On-Balance-Volume (OBV) line turned up to a new high to confirm the buying and so did the Moving Average Convergence Divergence (MACD) oscillator.
Here are four stocks to watch, three of which are moving on strong earnings reports. Anika Therapeutics Inc. (ANIK) popped $11.78, or 29%, to $52.60 on Thursday on 1.3 million shares traded, or about eight times its average volume. The breakaway gap, and continued runup, broke the stock through several layers of lateral resistance, with the next target at the $61 level last reached in early 2018.
Here are four stocks to watch, three of them moving on strong earnings: Anika Therapeutics, Inc . (NASDAQ: ANIK ) popped $11.78, or 28.8%, to $52.60 on Thursday on 1.3 million shares, or about 8x its average ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
Anika (ANIK) delivered earnings and revenue surprises of 59.52% and 6.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to exhibit its injectable, HA-based, surgical bone repair therapy at the 2019 American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting being held July 11-14 in Boston, Massachusetts at the Hynes Convention Center. “We’re excited to attend this year’s AOSSM Annual Meeting and showcase our HA-based bone repair therapy, which we will be launching in the U.S. this quarter,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. The AOSSM Annual Meeting focuses on providing information on frontline research to the orthopedic sports medicine community, allowing attendees to meet, educate and connect with top physicians in the field of sports medicine.
Anika Therapeutics, Inc. today announced that the Company plans to issue its second-quarter 2019 financial results after the close of the market on Wednesday, July 24, 2019 and hold its investor conference call on the same day, Wednesday, July 24, 2019, at 5:00 p.m.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
Anika Therapeutics, Inc. (ANIK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.